Core Viewpoint - Changjiang Life Science Technology (00775) has seen a significant stock increase of over 8%, currently trading at 1.01 HKD, with a transaction volume of 23.28 million HKD, following the presentation of its tumor growth inhibition research results at the SITC 2025 conference [1] Group 1: Company Developments - The company showcased major advancements in cancer vaccines targeting TROP2, PRAME, and PD-L1 at the SITC 2025 conference [1] - Dr. Du Jianming, Vice President and Chief Scientific Officer of the company, expressed optimism about the results of the cancer vaccine candidates targeting TROP2 and PRAME/PD-L1, indicating a potential acceleration in the development of effective therapeutic cancer vaccines [1] - The current goal for the company is to advance these vaccine candidates to the clinical trial stage [1]
港股异动 | 长江生命科技(00775)再涨超8% 公司展示抑制肿瘤生长研发成果 疫苗研究进程有望加速